Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)’. The study aims to evaluate the effectiveness and safety of Orforglipron, a once-daily oral medication, compared to a placebo in adolescents with obesity or overweight conditions accompanied by related health issues. This research is significant as it targets a growing health concern among adolescents, potentially offering a new treatment option.
Intervention/Treatment: The study tests Orforglipron, an experimental drug administered orally, against a placebo. Orforglipron is intended to address obesity and related comorbidities in adolescents, aiming to improve health outcomes in this demographic.
Study Design: This Phase 3 interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor investigators know who receives the treatment or placebo. The primary purpose is treatment-focused, aiming to assess the drug’s efficacy and safety.
Study Timeline: The study began on November 18, 2024, with a primary completion date yet to be announced. The latest update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
Market Implications: This study update could influence Eli Lilly’s stock performance positively if Orforglipron proves effective, as it would expand their portfolio in the obesity treatment market. Investor sentiment may be optimistic, given the increasing demand for adolescent obesity treatments. Competitors in the pharmaceutical industry will likely monitor these developments closely, as successful outcomes could shift market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.